Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
Ashwin Somasundaram, Timothy F Burns Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA Abstract: Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains poor.However, the approval of checkpoint blockade immunotherapy has shifted the